Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Climb Bio, Inc.CLYM · Entity 5064 | Chief Operating Officer | January 13, 2025 | January 15, 2025 |
| Compass Therapeutics, Inc.CMPX · Entity 5614 | Director | February 18, 2022 | February 23, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Climb Bio, Inc.
Report date January 13, 2025 · Filed January 15, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.92 · Expires 2035-01-12 | Direct | 500,000 |
Reported balance
After 2025-01-13 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-01-13 · Grant · Acquired 500,000 · Balance 500,000 F1: This option was granted on January 13, 2025 (the "Grant Date"). The shares underlying the option are scheduled to vest with respect to 25% of the shares on the first anniversary of the Grant Date and the remainder are scheduled to vest in 36 equal monthly installments through January 13, 2029, subject to the Reporting Person's continued service. |
Filing footnotes · ownership attribution and instrument terms
F1: This option was granted on January 13, 2025 (the "Grant Date"). The shares underlying the option are scheduled to vest with respect to 25% of the shares on the first anniversary of the Grant Date and the remainder are scheduled to vest in 36 equal monthly installments through January 13, 2029, subject to the Reporting Person's continued service.
Compass Therapeutics, Inc.
Report date February 18, 2022 · Filed February 23, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.40 · Expires 2032-02-17 | Direct | 30,000 |
Reported balance
After 2022-02-18 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-02-18 · Grant · Acquired 30,000 · Balance 30,000 F1: This option vests in substantially equal monthly installments over four years. |
Filing footnotes · ownership attribution and instrument terms
F1: This option vests in substantially equal monthly installments over four years.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Prevail Therapeutics Inc.
Report date January 22, 2021 · Filed January 26, 2021
Section 16 reporting ended · disclosed 2021-01-26. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.18 | Direct | 0 |
Reported balance
After 2021-01-22 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-01-22 · Disposition to issuer · Disposed 347,004 · Balance 0 F1: Pursuant to the terms of the Merger Agreement, and as of immediately prior to the Effective Time, each of these options, whether or not vested, was automatically cancelled, by virtue of the Merger and without any action on the part of the Reporting Person, and the Reporting Person was entitled to receive (A) an amount of cash (less applicable tax withholdings) equal to the product of (i) the excess, if any, of $22.50 per share of common stock underlying such stock option, net in cash, without interest, over the applicable exercise price per share underlying such stock option multiplied by (ii) the total number of shares subject to such stock option, and (B) one contingent value right per share for each share subject to such stock option immediately prior to the Effective Time (without regard to vesting). |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.26 | Direct | 0 |
Reported balance
After 2021-01-22 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-01-22 · Disposition to issuer · Disposed 64,565 · Balance 0 F1: Pursuant to the terms of the Merger Agreement, and as of immediately prior to the Effective Time, each of these options, whether or not vested, was automatically cancelled, by virtue of the Merger and without any action on the part of the Reporting Person, and the Reporting Person was entitled to receive (A) an amount of cash (less applicable tax withholdings) equal to the product of (i) the excess, if any, of $22.50 per share of common stock underlying such stock option, net in cash, without interest, over the applicable exercise price per share underlying such stock option multiplied by (ii) the total number of shares subject to such stock option, and (B) one contingent value right per share for each share subject to such stock option immediately prior to the Effective Time (without regard to vesting). |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.91 | Direct | 0 |
Reported balance
After 2021-01-22 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2021-01-22 · Disposition to issuer · Disposed 95,000 · Balance 0 F1: Pursuant to the terms of the Merger Agreement, and as of immediately prior to the Effective Time, each of these options, whether or not vested, was automatically cancelled, by virtue of the Merger and without any action on the part of the Reporting Person, and the Reporting Person was entitled to receive (A) an amount of cash (less applicable tax withholdings) equal to the product of (i) the excess, if any, of $22.50 per share of common stock underlying such stock option, net in cash, without interest, over the applicable exercise price per share underlying such stock option multiplied by (ii) the total number of shares subject to such stock option, and (B) one contingent value right per share for each share subject to such stock option immediately prior to the Effective Time (without regard to vesting). |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the terms of the Merger Agreement, and as of immediately prior to the Effective Time, each of these options, whether or not vested, was automatically cancelled, by virtue of the Merger and without any action on the part of the Reporting Person, and the Reporting Person was entitled to receive (A) an amount of cash (less applicable tax withholdings) equal to the product of (i) the excess, if any, of $22.50 per share of common stock underlying such stock option, net in cash, without interest, over the applicable exercise price per share underlying such stock option multiplied by (ii) the total number of shares subject to such stock option, and (B) one contingent value right per share for each share subject to such stock option immediately prior to the Effective Time (without regard to vesting).
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 13, 2025 Filed Jan 15, 2025 21:15 UTC | Climb Bio, Inc. CLYM · Entity 5064 | GrantStock Option (Right to Buy) · Derivative | 500,000 | $0.00 Strike: $1.92 | $0.00 |
DisclosureSEC source: 0000950170-25-005836 · ownership.xml · derivative · entry 1 Kaplan Brett · CIK 0001778763 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 500,000 Underlying: Common Stock · 500,000 shares Expires 2035-01-12 F1 · derivative.exercise_date: This option was granted on January 13, 2025 (the "Grant Date"). The shares underlying the option are scheduled to vest with respect to 25% of the shares on the first anniversary of the Grant Date and the remainder are scheduled to vest in 36 equal monthly installments through January 13, 2029, subject to the Reporting Person's continued service. Read SEC document |
| August 26, 2024 Filed Aug 26, 2024 21:47 UTC | Climb Bio, Inc. ELYM · Entity 5064 | GrantRestricted Stock Units · Derivative | 77,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-100633 · ownership.xml · derivative · entry 2 Kaplan Brett · CIK 0001778763 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 77,500 Underlying: Common Stock · 77,500 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the issuer's common stock upon vesting. F3 · derivative.exercise_date: The RSUs were granted on the Grant Date and are scheduled to vest over four years, with 25% of the shares vesting on each of the first four anniversaries of the Grant Date, subject to the Reporting Person's continued service. F3 · derivative.expiration_date: The RSUs were granted on the Grant Date and are scheduled to vest over four years, with 25% of the shares vesting on each of the first four anniversaries of the Grant Date, subject to the Reporting Person's continued service. Read SEC document |
| August 26, 2024 Filed Aug 26, 2024 21:47 UTC | Climb Bio, Inc. ELYM · Entity 5064 | GrantStock Option (Right to Buy) · Derivative | 465,000 | $0.00 Strike: $5.95 | $0.00 |
DisclosureSEC source: 0000950170-24-100633 · ownership.xml · derivative · entry 1 Kaplan Brett · CIK 0001778763 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 465,000 Underlying: Common Stock · 465,000 shares Expires 2034-08-25 F1 · derivative.exercise_date: This option was granted on August 26, 2024 (the "Grant Date"). The shares underlying the option are scheduled to vest with respect to 25% of the shares on the first anniversary of the Grant Date and the remainder are scheduled to vest in 36 equal monthly installments through August 26, 2028, subject to the Reporting Person's continued service. Read SEC document |
| February 18, 2022 Filed Feb 23, 2022 22:45 UTC | Compass Therapeutics, Inc. CMPX · Entity 5614 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $2.40 | $0.00 |
DisclosureSEC source: 0000899243-22-007424 · doc4.xml · derivative · entry 1 Kaplan Brett · CIK 0001778763 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2032-02-17 F1 · derivative.exercise_date: This option vests in substantially equal monthly installments over four years. Read SEC document |
| January 22, 2021 Filed Jan 26, 2021 17:14 UTC | Prevail Therapeutics Inc. PRVL · Entity 11821 | Disposition to issuerStock Option (Right to Buy) · Derivative | 95,000 | $0.00 Strike: $16.91 | $0.00 |
DisclosureSEC source: 0001209191-21-005435 · doc4.xml · derivative · entry 3 Kaplan Brett · CIK 0001778763 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 95,000 shares Expires not disclosed F1 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, and as of immediately prior to the Effective Time, each of these options, whether or not vested, was automatically cancelled, by virtue of the Merger and without any action on the part of the Reporting Person, and the Reporting Person was entitled to receive (A) an amount of cash (less applicable tax withholdings) equal to the product of (i) the excess, if any, of $22.50 per share of common stock underlying such stock option, net in cash, without interest, over the applicable exercise price per share underlying such stock option multiplied by (ii) the total number of shares subject to such stock option, and (B) one contingent value right per share for each share subject to such stock option immediately prior to the Effective Time (without regard to vesting). F1 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, and as of immediately prior to the Effective Time, each of these options, whether or not vested, was automatically cancelled, by virtue of the Merger and without any action on the part of the Reporting Person, and the Reporting Person was entitled to receive (A) an amount of cash (less applicable tax withholdings) equal to the product of (i) the excess, if any, of $22.50 per share of common stock underlying such stock option, net in cash, without interest, over the applicable exercise price per share underlying such stock option multiplied by (ii) the total number of shares subject to such stock option, and (B) one contingent value right per share for each share subject to such stock option immediately prior to the Effective Time (without regard to vesting). Read SEC document |
| January 22, 2021 Filed Jan 26, 2021 17:14 UTC | Prevail Therapeutics Inc. PRVL · Entity 11821 | Disposition to issuerStock Option (Right to Buy) · Derivative | 64,565 | $0.00 Strike: $10.26 | $0.00 |
DisclosureSEC source: 0001209191-21-005435 · doc4.xml · derivative · entry 2 Kaplan Brett · CIK 0001778763 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 64,565 shares Expires not disclosed F1 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, and as of immediately prior to the Effective Time, each of these options, whether or not vested, was automatically cancelled, by virtue of the Merger and without any action on the part of the Reporting Person, and the Reporting Person was entitled to receive (A) an amount of cash (less applicable tax withholdings) equal to the product of (i) the excess, if any, of $22.50 per share of common stock underlying such stock option, net in cash, without interest, over the applicable exercise price per share underlying such stock option multiplied by (ii) the total number of shares subject to such stock option, and (B) one contingent value right per share for each share subject to such stock option immediately prior to the Effective Time (without regard to vesting). F1 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, and as of immediately prior to the Effective Time, each of these options, whether or not vested, was automatically cancelled, by virtue of the Merger and without any action on the part of the Reporting Person, and the Reporting Person was entitled to receive (A) an amount of cash (less applicable tax withholdings) equal to the product of (i) the excess, if any, of $22.50 per share of common stock underlying such stock option, net in cash, without interest, over the applicable exercise price per share underlying such stock option multiplied by (ii) the total number of shares subject to such stock option, and (B) one contingent value right per share for each share subject to such stock option immediately prior to the Effective Time (without regard to vesting). Read SEC document |
| January 22, 2021 Filed Jan 26, 2021 17:14 UTC | Prevail Therapeutics Inc. PRVL · Entity 11821 | Disposition to issuerStock Option (Right to Buy) · Derivative | 347,004 | $0.00 Strike: $0.18 | $0.00 |
DisclosureSEC source: 0001209191-21-005435 · doc4.xml · derivative · entry 1 Kaplan Brett · CIK 0001778763 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 347,004 shares Expires not disclosed F1 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, and as of immediately prior to the Effective Time, each of these options, whether or not vested, was automatically cancelled, by virtue of the Merger and without any action on the part of the Reporting Person, and the Reporting Person was entitled to receive (A) an amount of cash (less applicable tax withholdings) equal to the product of (i) the excess, if any, of $22.50 per share of common stock underlying such stock option, net in cash, without interest, over the applicable exercise price per share underlying such stock option multiplied by (ii) the total number of shares subject to such stock option, and (B) one contingent value right per share for each share subject to such stock option immediately prior to the Effective Time (without regard to vesting). F1 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, and as of immediately prior to the Effective Time, each of these options, whether or not vested, was automatically cancelled, by virtue of the Merger and without any action on the part of the Reporting Person, and the Reporting Person was entitled to receive (A) an amount of cash (less applicable tax withholdings) equal to the product of (i) the excess, if any, of $22.50 per share of common stock underlying such stock option, net in cash, without interest, over the applicable exercise price per share underlying such stock option multiplied by (ii) the total number of shares subject to such stock option, and (B) one contingent value right per share for each share subject to such stock option immediately prior to the Effective Time (without regard to vesting). Read SEC document |
| September 10, 2020 Filed Sep 15, 2020 00:02 UTC | Compass Therapeutics, Inc. NONE · Entity 5614 | GrantStock Option (Right to Buy) · Derivative | 60,000 | $0.00 Strike: $5.00 | $0.00 |
DisclosureSEC source: 0000899243-20-025035 · doc4.xml · derivative · entry 1 Kaplan Brett · CIK 0001778763 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2030-09-10 F1 · derivative.exercise_date: This option shall vest in substantially equal monthly installments over four years. Read SEC document |
| February 19, 2020 Filed Mar 11, 2020 16:51 UTC | Prevail Therapeutics Inc. PRVL · Entity 11821 | GrantStock Option (Right to Buy) · Derivative | 95,000 | $0.00 Strike: $16.91 | $0.00 |
DisclosureSEC source: 0001209191-20-018123 · doc4.xml · derivative · entry 1 Kaplan Brett · CIK 0001778763 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,000 Underlying: Common Stock · 95,000 shares Expires 2030-02-19 F1 · derivative.exercise_date: 25% of the total number of shares underlying the option vest and become exercisable on February 19, 2021 and an additional 1/48th of the total number of shares underlying the option shall vest and become exercisable on the same date of each of the thirty-six (36) consecutive months thereafter subject, in all cases, to the Reporting Person providing continuous service with the Issuer on each such date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.